Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2018

  • ID: 4576094
  • Report
  • 37 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Medinova AG
  • Mithra Pharmaceuticals SA
  • TherapeuticsMD Inc
  • MORE
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2018, provides an overview of the Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline landscape.

Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary tract infections and urinary incontinence. Risk factor includes smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is decreased or restricted. Treatment includes topical (vaginal) estrogen and systemic estrogen therapy.

Report Highlights:

This latest pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, IND/CTA Filed and Preclinical stages are 1, 1, 1 and 2 respectively.

Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis) (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Medinova AG
  • Mithra Pharmaceuticals SA
  • TherapeuticsMD Inc
  • MORE
Introduction

Report Coverage

Vaginal Atrophy (Atrophic Vaginitis) - Overview

Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development

Ligand Pharmaceuticals Inc

Medinova AG

Mithra Pharmaceuticals SA

TherapeuticsMD Inc

Vaginal Atrophy (Atrophic Vaginitis) - Drug Profiles

(estriol + lactobacillus) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Estetrol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lasofoxifene tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TX-006HR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TX-008HR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects

Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones

Featured News & Press Releases

May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor

Feb 10, 2016: Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International Society for the Study of Women's Sexual Health Meeting

Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Ligand Pharmaceuticals Inc, H1 2018

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Medinova AG, H1 2018

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Mithra Pharmaceuticals SA, H1 2018

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by TherapeuticsMD Inc, H1 2018

Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Ligand Pharmaceuticals Inc
  • Medinova AG
  • Mithra Pharmaceuticals SA
  • TherapeuticsMD Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll